The new share buyback program comes in addition to the $6.4 billion remaining under current authorization.
The quarterly dividend was raised from 32 cents to 34 cents per share, which equates to an annual dividend of $1.36 per share. The increased dividend will be payable to shareholders Mar. 1, 2018.
More articles on supply chain:
FDA cracks down on homeopathic drugs
Teva Pharmaceuticals to cut more than 25% of workforce, consolidate US sites
Two months after approval, Gilead’s ‘breakthrough’ cancer drug given to just a handful of patients
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
